The collaboration began in 2003 with Celgene. The collaboration produced a compound that led to a clinical candidate currently being evaluated for the treatment of fibrotic and inflammatory diseases.

 

Clinical Trial:

Phase II trial for the treatment of Idiopathic Pulmonary Fibrosis